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Background: This study is to analyze promoter methylation of various tumor suppressor genes in different types of
ovarian carcinoma and to identify potential therapeutic targets of ovarian clear cell adenocarcinoma (OCCA).
Materials and methods: The promoter methylation statuses of 40 genes in primary ovarian carcinomas including
47 clear- and 63 non-clear-cell type tissues, 6 OCCA cell lines, 29 benign ovarian endometriotic cysts, and 31 normal
controls were analyzed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). The
MS-MLPA results were correlated with clinicopathological features and outcomes of 47 OCCA patients. Functions of
the target genes were further explored by Western Blot Analysis, apoptosis assay, and caspase-3/7 activity analysis.
Results: Frequencies of methylated RASSF1A, CDH13, CACNA1A, HIN-1, and sFRP5 genes in OCCA tissues were
significantly higher than those in non-OCCA cancerous tissues and benign endometriotic cysts. The expected OS
for patients with methylated promoters of HIN-1 was significantly worse than those for patients without methylated
HIN-1 (30% vs. 62%, p= 0.002). The HIN-1 gene was over-expressed in ES2 cells, a significant reduction in cell
growth and induction of apoptosis, and increasing paclitaxel sensitivity by reducing phosphorylation of Akt were
observed.
Conclusions: Methylation of HIN-1 promoter is a novel epigenetic biomarker associated with poor outcomes in
OCCA patients. Ectopic expression of the HIN-1 gene increased paclitaxel sensitivity which is partly through Akt
pathway.
Keywords: Ovarian clear cell adenocarcinoma, Methylation-specific multiplex ligation-dependent probe
amplification, HIN-1, CACNA1AIntroduction
Ovarian clear cell adenocarcinoma (OCCA) is recog-
nized as a distinct histological type of cancer, and its fre-
quency among epithelial ovarian cancers is estimated to
be less than 10% [1,2]. However, the overall frequency of
OCCA is higher in Taiwan at about 15-20% of epithelial
ovarian cancers [3]. OCCA clinically differs from other
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reproduction in any medium, provided the orresistance to platinum-based chemotherapies, and it
shows a poor prognosis [3-5].
The molecular pathogenesis of OCCA is still unclear
and needs to be elucidated to improve patient outcomes.
However, hepatocyte nuclear factor-1β is upregulated in
OCCA cells compared to non-OCCA cells, and was
reported to be essential for the survival of patients [6].
Higher p21 and cyclin E with lower TP53 and cyclin A
levels were detected in OCCA compared to other epi-
thelium ovarian cancers, and they are thought to be
involved in the carcinogenesis of OCCA [7]. Silencing of
Wilms tumor suppressor 1 sense and antisense genes by
promoter methylation in OCCA revealed the epigenetic
involvement of OCCA in carcinogenesis as distinguishedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high percentage of promoter methylation of the sFRP5
gene in OCCA indicated its importance in the develop-
ment of OCCA and is a potentially useful marker for
prognoses and treatment targeting of OCCA [9]. Neither
PTEN promoter methylation nor loss of homozygosity
(LOH) at the 10q23 locus was significantly related to
PTEN inactivation, which is often detected in OCCA
[10]. Activating mutations in the PIK3CA gene [11] and
genomic amplification of chr20q13.2 [12] are also com-
mon genetic alterations identified with OCCA. Recently,
mutations at PPP2R1A and ARID1A were found, and it
was suggested that aberrant chromatin remodeling may
contribute to the pathogenesis of OCCA, indicating that
epigenetic changes in cancer cells may occur through
specific modifications of chromatin proteins [13].
Hypermethylation of CpG islands within the regula-
tory region of tumor suppressor genes (TSGs) is one of
the earliest and most frequent alterations; it results in
gene silencing and confers a growth advantage on tumor
cells [14]. Distinct patterns of DNA methylation among
different tumors may be a useful signature for diagnosis
and prognosis [15]. Loss of sFRP5 was recently reported
to be an aberrant molecular event in OCCA and a pos-
sible prognostic marker [9]. Cellular events affected by
epigenetic alterations include DNA repair, cell cycling
control, adherence, apoptosis, and detoxification [16].
Thus, a complicated epigenetic network is thought to be
involved in OCCA carcinogenesis. We hereby hypothe-
sized that additional cancer-related genes with aberrant
methylation modified promoters possibly contribute to
the pathogenesis and progression of OCCA. As the
number of methylated genes revealed in cancer is in-
creasing, sensitive and robust multiplex methods for
detecting the methylation status of promoter regions are
desirable. Therefore, a methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA)
analysis was applied to determine the TSG promoter
methylation profile of OCCA.
Materials and methods
Cell lines and cultures
OCCA cell lines including HAC-2, KK, RMG-I, RMG-II,
and ES-2 cells, and two immortalized cell lines, OSE2a
and OSE2b-2 (tumorigenic), were cultured and main-
tained as described previously [10]. TOV21G was
obtained from American Type Culture Collection
(ATCC) and maintained in MCDB 105/medium 199 sup-
plemented with 10% heat-inactivated fetal bovine serum.
Patients and specimens
Tissue samples were obtained from surgical specimens
with the informed consent of patients at Cathay General
Hospital (CGH) after this project being approved by theInstitutional Review Board of the hospital. Tissues were
taken only from cancerous regions during surgery were
immediately frozen at −80°C until analysis and each
sample was confirmed pathologically to have high neo-
plastic cellularity (> 66%).
In total, 110 primary human epithelial ovarian carcin-
oma samples, comprising 47 OCCA and 63 non-OCCA
tissues, and 29 benign endometriotic cysts were col-
lected between 1994 and 2005. The histologic grading
was based on International Union against Cancer
criteria, while staging was according to the criteria set
by the International Federation of Gynecology and
Obstetrics [17].
Preexisting clinical information, including age, meno-
pausal status, treatment history, surgical findings dur-
ing debulking, recurrence status, and survivorship was
collected from clinical and operative notes and the dis-
charge summary that were deposited in a centralized
database. The maximal diameter of the residual tumor
during surgery was also recorded. Optimal debulking
surgery was defined as the maximal diameter of the
residual tumor of < 1 cm or otherwise defined as sub-
optimal debulking surgery. Patients received regular
follow-up after completion of treatment. Computed
tomography (CT) or magnetic resonance imaging
(MRI) was performed when recurrence was suspected.
Abnormal results of imaging studies, aspiration cy-
tology from ascites, elevated tumor markers such as
CA125 (≥ 2-fold of the upper normal limit) on two
consecutive tests within a 2-week interval, or tissue
proven from biopsy, if possible, was defined as recur-
rence [18]. Progression-free survival was measured as
the period from the operation to the date of con-
firmed recurrence or disease progression, or the date
of the investigators’ last note of a disease-free status.
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
MS-MLPA with SALSA MLPA kits such as ME001B and
ME003-A1 (MRC-Holland, Amsterdam, the Netherlands)
are commercially available kits which were applied with
specifically designed probe sets to detect the methylation
status in the promoter regions of 40 TSGs (Table 1).
These 40 TSG were reported to be associated with cancer
in the literature. All control probes that were not influ-
enced by Hha I digestion were included. The MS-MLPA
reaction was performed according to the MRC-Holland’s
user guide with some modifications [19]. In brief, 300 ng
of genomic DNA from respective tissue samples or cell
lines was used. The MS-MLPA probes were hybridized to
denatured genomic DNA for 16 h at 60°C, then divided
into two aliquots. One aliquot was ligated and digested
with the methylation-sensitive Hha I restriction enzyme,
and the other was ligated but without Hha I digestion.
Table 1 Genes represented by probe mixtures (ME001B and ME003-A1)
ME001B ME003-A1
Gene Chromosonal position UniGene Gene Chromosomal position UniGene
APC 5q21 Hs.158932 BCL2 18q21.3 Hs.150749
ATM 11q23 Hs.367437 BNIP3 10q26.3 Hs.144873
BRCA1 17q21 Hs.194143 CACNA1A 19p13.2 Hs.501632
BRCA2 13q12 Hs.34012 CACNA1G 17q21.33 Hs.591169
CASP8 2q33-q34 Hs.599762 CCND2** 12p13.3 Hs.376071
CD44 11p13 Hs.502328 DLC1** 8p22 Hs.134296
CDG13 16q24.2 Hs.654386 H2AFX** 11q23.3 Hs.477879
CDKN1B 12p13.1 Hs.238990 ID4** 6p22.3 Hs.519601
CDKN2A 9p21 Hs.238990 PRDM2 1p36.21 Hs.371823
CDKN2B 9p21 Hs.72901 RARB* 3p24 Hs.654490
CHFR 12q24.33 Hs.656770 RUNX3 1p36.11 Hs.170019
DAPK1 9q34.1 Hs.380277 SCG3A1** 5q35 Hs.62492
ESR1 6q25.1 Hs.208124 SFRP4** 7p14.1 Hs.658169
FHIT 3p14.2 Hs.715588 SFRP5** 10q24.1 Hs.279565
GSTP1 11q13 Hs.523836 SMARCA3** 3q25.1 Hs.3068
HIC1 17p13.3 Hs.72956 TGIF 18p11.31 Hs.373550
IGSF4 11q23 Hs.370510 TIMP3 22q12.3 Hs.644633
MLH1 3p21.3 Hs.195364 TWIST1 7p21.2 Hs.66744
PTEN 10q23.31 Hs.500466
RASSF1 3p21.3 Hs.476270 Hs.
TP73 1p36 Hs.697294
VHL 3p26-p25 Hs.517792
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tion (PCR) using fluorescently labeled primers to produce
a uniquely sized product. Following restriction digestion,
probe-targeting sequences containing unmethylated Hha I
sites could not be amplified. PCR products were examined
by capillary electrophoresis on an ABI 3100 genetic
analyzer, using GENESCAN software (version 3.5.1, Ap-
plied Biosystems). Peak identification and values corre-
sponding to peak size in base pairs (bp), and peak areas
were further processed to obtain data, which were then
normalized to control DNA and extracted using Coffalyser
software (version 9.4, MRC-Holland). For the hyper-
methylation analysis, the “relative peak value” or the
“probe fraction” of the ligation-digestion sample was
divided by the “relative peak value” of the corresponding
undigested ligation sample, resulting in a “methylation-
ratio” (M-ratio). Aberrant methylation was scored when
the calculated M-ratio was≥ 0.30, corresponding to 30%
methylated DNA. Values of 0.00~0.29 of the M-ratio
were interpreted as the absence of hypermethylation.
When the percentage ratio was < 30%, it was relegated to
background noise. M-ratios of 0.30~0.49 were recognized
as mild hypermethylation, 0.50~ 0.69 as moderate hyper-
methylation, and > 0.70 as extensive hypermethylation. Forreaction-targeted genes with more than one probe, M-
ratios were independently calculated for the methylation
analysis, and we also used the previously described math-
ematical algorithm cutoff ratio for a peak height of≥ 30%
[20,21].
Sodium bisulfite treatment, sequencing, and methylation
specific-PCR analyses of the genome
Genomic DNA was isolated using a Genomic DNA kit
(Geneaid Biotech, Bade City, Taiwan), converted with so-
dium bisulfite in the CpGenome DNA modification kit
(Millipore, MA, USA), purified, and then amplified by a
PCR with DNA polymerase (ThermoHotStart 2X Gold
PCR Master mix; Applied Biosystems) and HIN-1-
specific primers. The primer sequences for methylated
HIN-1 were 5’-GAAGTTTCGTGGTTTTGTTCG-3’ (for-
ward) and 5’-AAAACCTAAAATCCACGATCGAC-3’
(reverse); and the primer sets for unmethylated HIN-1
were 5’-TAAGAAGTTTTGTGGTTTTGTTTGG-3’ (for-
ward) and 5’-AAAAAACCTAAAATCCACAATCAAC-3’
(reverse). Bisulfite-modified, Sss I (New England Biolabs,
MA)-treated normal lymphocyte DNA served as the
methylated control, and bisulfite-treated normal lympho-
cyte DNA was the unmethylated control. PCR products
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specific-PCR in a final volume of 20 μl was performed
under the following conditions: 95°C for 10 min, followed
by 40 cycles of 95°C for 30 s, 62°C for 30 s, and 72°C 40 s;
with a final extension at 72°C for 10 min and holding at
4°C. PCR products were purified and then directly
sequenced using an Applied Biosystems ABI automated
DNA sequencer.
5-Aza-2-deoxycytidine treatment and reverse-
transcription real-time quantitative (RT-qPCR) analysis
Cells were treated with 10 μM of 5-aza-2-deoxycytidine
(5-aza-2-dC; Sigma, St. Louis, MO, USA), and renewed
every 24 h. An RT-qPCR analysis was used to measure
HIN-1 messenger RNA in response to treatment. Consti-
tutively expressed GAPDH was used as an internal con-
trol. The qPCR was performed in an ABI Prism 7300
Sequence Detection System (Applied Biosystems) with
Taqman Gene Expression Assay Hs00369360g1 and pri-
mers as described above. The conditions were as follows:
2 min at 50°C, 10 min at 95°C, and then 40 cycles of 95°C
for 15 s and 60°C for 1 min. The interpolated number (Ct)
of cycles to reach a fixed threshold above the background
noise was used to quantify amplification.
Western blot analysis
Cell lysates were prepared using a protein extraction so-
lution (iNtRON Biotechnology, Kyunggi-do, Korea),
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (12%) and transferred to a
polyvinylidene difluoride (PVDF) membrane. The mem-
brane was blocked in TBS blocking buffer (0.2% Tween
20 and 3% bovine serum albumin) and incubated with
the indicated antibodies for 1 h. After washing, a
peroxidase-conjugated rabbit-anti-goat immunoglobulin
G was applied, and the bound antibodies were visualized
by development with NBT/BCIP as the chromogenes.
The GST-HIN-1 fusion protein was used as a positive
control. An affinity-purified anti-human β-actin rabbit
polyclonal antibody (Santa Cruz Biotechnology, CA) was
applied to normalize the signals generated by the anti-
Hin-1 antibody (Santa Cruz Biotechnology).
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded specimens were
sliced by a microtome at a thickness of 1 ~ 3 μm and
placed on coated slides. Tissue slides were then incu-
bated with a purified goat polyclonal antibody of UGRP2
(S-15) (Santa Cruz Biotechnology) using a Thermo Sci-
entific Autostainer 360 (Thermo Fisher Scientific Inc,
CA). The expression was scored as 0, 1, 2, or 3 accord-
ing to the intensity. Tissues with > 10% of neoplastic cells
and expressing a score of 2 ~ 3 intensity were recognized
as positive. Percentages of each score in positive tissueswere further recorded. A pathologist not involved in the
present study evaluated the immunostaining under
blinded conditions.
Plasmid DNA construction, preparation, and transfection
HIN-1 full-length complementary DNA (cDNA) was
amplified by a PCR using human placenta cDNA
as the template and primers of 5′-GAATTCATGA
AGCTCGCCGCCCTCC-3′ and 5′-CTCGAGTCAGCCA
AACACTGTCAGGG-3′. The amplified product was
cloned into EcoR I/Xho I sites of pcDNA3.1 (Invitro-
gen), and then confirmed by sequencing.
ES-2 cells (3x105 cells/well of 6-well plate) were trans-
fected with an HIN-1 expression plasmid using FuGENE
HD (Roche Applied Science) according to the manufac-
turer’s protocol. Transfected ES-2 cells were selected
with 400 μg/ml G418 (Invitrogen). Stably transfected
cells with the Hin-1-expression plasmid (ES-2-Hin-1) or
with an empty vector (ES-2-PCDNA3.1) were main-
tained with 200 μg/ml of G418.
Drug treatment and cell growth assays
ES-2-Hin-1 or ES-2-PCDNA3.1 cells were plated at
1x104 cells/well in 6-well plates for 24 h, and treated
with different concentrations of paclitaxel for the indi-
cated times. The culture medium was changed every
2 days. The number of viable cells after paclitaxel treat-
ment was counted with a trypan blue dye exclusion
assay in a hemocytometer.
Annexin V apoptosis assay and caspase-3/7 activity
analysis
Apoptosis-positive cells were analyzed with an FITC
Annexin V apoptosis detection kit I (BD Biosciences)
according to the manufacturer’s protocol with minor
modifications. Briefly, ES2 cells were seeded in 12-well
chamber slides (ibidi, Martinsried, Germany) at a density
of 7500 cells/well for 24 h and treated with 25 nM taxol
or 4 μM cisplatin for 6 h. Each well was washed with
wash buffer (20 mM Tris (pH 7.4) 150 mM NaCl, and
1 mM CaCl2) following a 15-min incubation in binding
buffer containing Annexin V-FITC and propidium iod-
ide (PI) at room temperature in the dark. Afterwards,
apoptotic images were caught on a fluorescence micro-
scope (Nikon ECLIPSE 80i). Additional evidence for the
occurrence of apoptosis was quantitatively determined
by the activity of cellular caspase-3/7 using Caspase-
Glo 3/7 assays (Promega) according to the manufac-
turer’s instructions. Briefly, ES2 cells were seeded and
treated with paclitaxel as described above. After 24 h,
cells were lysed and luminogenic substrates specific for
the caspase species were added. Light emission was
measured in a luminometer (Berthold Technologies,
Wildbad, Germany).
Table 2 Frequencies of promoter methylation which
significantly differ in between ovarian clear cell
adenocarcinoma and benign endometriotic cysts
Percentage (case number)
Gene name Clear cell Benign ovarian cyst p value
n=47 N=29
RASS328 72% (34) 0% (0) <0.001
RASS382 77% (36) 0% (0) <0.001
APC 15% (7) 0% (0) 0.029
CDKN2A 2% (1) 20% (6) 0.006
CDH13 47% (22) 0% (0) <0.001
SCG148 40% (19) 14% (4) 0.014
SCG409 13% (6) 0% (0) 0.046
SFRP5211 23% (11) 0% (0) 0.004
CCND2220 30% (14) 6% (2) 0.001
CCND2142 51% (24) 24% (7) 0.02
CACNA1A 43% (20) 0% (0) <0.001
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ES-2-Hin-1 or ES-2-PCDNA3.1 cells were plated over-
night and starved in serum free medium for 24 hours.
Then the cells were cultured in complete medium with
15nM paclitaxel for indicated intervals. Western blot
analysis was performed as described above. Briefly, three
antibodies (anti- AKT, anti-phospho-AKTThr308, and
anti-phospho-AKTSer473) (Cell Signaling, Beverly, MA)
were used.
Statistical analysis
Statistical analyses were performed using the SPSS stat-
istical package (SPSS 16.0.1 for Windows 2008, Chicago,
IL). Frequencies of promoter methylation of 40 genes
were compared using a Chi-squared test. Survival curves
were generated using the Kaplan-Meier method. Differ-
ences in survival curves were calculated using the log-
rank test. Cox’s univariate and multivariate regression
analyses were used to evaluate prognostic factors for sur-
vival. A p value < 0.05 was regarded as statistical
significance.
Results
The mean age of the 47 OCCA patients was 50 (range,
32 ~ 66) years. The distribution of stages was 4 at stage
IA, 13 at IC, 2 at IIA, 4 at IIC, 1 at IIIA, 18 at IIIC, and
5 at IV. The percentages of optimal and suboptimal
debulking surgeries were 72.3% and 27.7%. Twenty-eight
(60.9%) of them had preoperative CA125 serum level
higher than 500 IU/ml.
All OCCA patients underwent staging laparotomy and
initial cytoreductive surgery followed by both paclitaxel-
platinum-based chemotherapy. The median number of
cycles was six (range: 4–9 cycles). Clinical response was
assessed in patients with clinically measurable disease,
according to WHO criteria, or assessed in patients with
nonmeasurable disease, according to normal physical
examinations, computed tomography of the abdomen or
pelvis and chest X-ray, and CA125 <35 U/ml. Cytore-
duction was optimal (residual disease less than 1 cm) in
13 of the 24 patients (54%) with stage III and IV OCCA,
and was suboptimal in 11 patients (46%). For patients
with stage III and IV OCCA, 58.3% (14/24) had
complete or partial response to chemotherapy. However,
patients with stage III and IV OCCA exhibited a 54%
(13/24) high rate of platinum resistance (recurrence oc-
curred in 6 months after completing chemotherapy) or
refractory (disease progression during chemotherapy).
MS-MLPA profiling of TSG promoter methylation in OCCA
cell lines
We first evaluated TSG promoter methylation by MS-
MLPA on the OCCA cell lines- ES2, KK, HAC-2, RMG-
1, RMG-2, and TOV21G. Promoters of RASSFIA1,HIN-1, ID4, sFRP4, sFRP5, CCND2, CDH13, and CAC-
NA1A genes were found to be methylated in at least two
of the six analyzed OCCA cell lines.
These results suggest that these genes could be epi-
genetic candidates to distinguish aberrant methylation in
human OCCA tissues.
MS-MLPA profiles of TSG promoter methylation in OCCA
tissues
We further evaluated TSG promoter methylation of
OCCA tissues by MS-MLPA. Eight of the 40 TSG pro-
moters showed significantly higher frequencies of hyper-
methylation in OCCA tissues compared to benign
ovarian cysts (Table 2). The most frequently hyper-
methylated genes in OCCA tissues analyzed by MS-
MLPA in order were RASSFIA (77%), CCND2 (51%),
CDH13 (47%), CACNA1A (43%), HIN-1 (40%), sFRP5
(23%), ID4 (19%), APC (15%), RUX3 (13%), GSTP1 (9%),
TP73 (6%), and TIMP3 (4%). RASSFIA1, CCND2,
CDH13, CACNA1A, HIN-1, sFRP5, and ID4 genes that
were frequently methylated in OCCA specimens over-
lapped with those found to be methylated in the OCCA
cell lines as shown above. Moreover, the methylation fre-
quencies of RASSFIA, CDH13, CACNA1A, HIN-1,
DKN2B, sFRP5, ID4, and ESR were significantly higher
among OCCA than those in non-clear-cell types of ovar-
ian carcinoma (Table 3).
Endometriosis was reported to be a precursor lesion
of OCCA. We next examined methylated genes in
OCCA with and without endometriosis. When we com-
pared those genes with methylated promoters in sam-
ples of OCCA with and without endometriosis, only
CACNA1A had a significantly higher promoter methy-
lation status in OCCA samples without endometriosis
Table 3 Frequencies of promoter methylation which
differ significantly between ovarian clear cell
adnocarcinoma and non-OCCA tissues
Percentage (case number/total)
Gene name Clear cell Non-clear cell p value
(n=47) (n=63)
RASS328 72% (34) 16% (10) <0.001
RASS382 77% (36) 17% (11) <0.001
ESR1 9% (4) 0% (0) 0.018
CDKN2B 28% (13) 5% (3) 0.001
CDKN1B 6% (3) 0% (0) 0.042
CDH13 47% (22) 11% (7) <0.001
BRCA1 0% (0) 17% (11) 0.002
SCG148 40% (19) 8% (5) 0.001
ID4346 19% (9) 5% (3) 0.016
SFRP382 11% (5) 0% (0) 0.008
SFRP5211 23% (14) 6% (4) 0.01
CACNA1A 43% (20) 11% (7) <0.001
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metriosis (0%, 0/8) (p= 0.013). And the promoter
methylation of CACNA1A was found in benign endo-
metriotic cysts.
Our results indicate that methylation of various genes
were specifically related with OCCA instead of the other
histologic types of ovarian cancer. And the methylation
of CACNA1A gene only participates in the carcinogen-
esis of OCCA without endometriosis.MS-MLPA profiles related to clinical outcome of OCCA
patients
We then evaluated the correlation between TSG pro-
moter methylation and the progression-free survival
(PFS) and overall survival (OS) of OCCA patients. With
a median follow-up of 56 months, the expected 5-year
PFS and OS for patients with methylated promoters of
HIN-1 and CACNA1A genes were significantly worse
than those for patients without methylated HIN-1 (28%
vs. 54%, p= 0.047 for PFS; 30% vs. 62%, p= 0.002 for OS,
respectively) (Figure 1A) and CACNA1A (30% vs. 63%,
p= 0.01 for PFS; 40% vs. 75%, p= 0.02 for OS)
(Figure 1B). Suboptimal surgery, advanced FIGO stages,
HIN-1 methylation, CACNA1A methylation, and a
higher preoperative CA125 level (> 500 U/ml) were poor
prognostic factors for OS of these patients by univariate
analysis. Only HIN-1 methylation, (hazard ratio (HR)
13.03, 95% confidence interval (CI) 2.50 ~ 68.58) and
CACNA1A methylation (HR 4.30, 95% CI 1.40 ~ 13.27)
were independent poor prognostic factors by the multi-
variate analysis (Figure 1).Validation of promoter methylation of the HIN-1 gene
with MS-PCR and sodium bisulfite sequencing in samples
of OCCA cell lines
Bisulphite sequencing of CpGs of six OCCA cell lines
(ES-2, KK, HAC-2, RMG-1, RMG-2, and TOV21G) and
OSE2A and OSE2B was analyzed. The MS-MLPA and
MS-PCR probes and amplicon locations within the
HIN-1 gene promoter are shown in Figure 2. A sum-
mary of the bisulphite sequencing results of HIN-1 in
OCCA cell lines is given in Figure 3A. All CpGs were
completely methylated in the KK and HAC-2 cell lines,
were almost completely methylated in the RMG-1 cell
line, and were partially methylated in the ES-2 and
TOV21G cell lines. However, almost complete unmethy-
latation of the RMG-2 cell line was noted. Methylation
of specific CpG sites in OCCA cell lines detected by the
MS-PCR was in accordance with bisulphite sequencing
of the promoter region of HIN-1. A representative figure
of promoter methylation of HIN-1 in OCCA cell lines
detected by MS-PCR is shown in Figure 3B. Similar
findings were found in OCCA tissues. A summary of the
bisulphite sequencing results of HIN-1 in OCCA tissues
is given in Figure 3C. A representative figure of pro-
moter methylation of HIN-1 in OCCA tissues detected
by MS-PCR is shown in Figure 3D. The MS-PCR and
MS-MLPA analyses of promoter methylation of the
HIN-1 gene in 47 OCCA tissues showed good correla-
tions (κ= 0.782).Promoter methylation and loss of expression of HIN-1 in
OCCA tissues
We then checked the impact of promoter hypermethy-
lation on the expression of the HIN-1 gene. The mRNA
level of HIN-1 had a reversed correlation with its
methylation status in OCCA cell lines, cancerous tis-
sues, and benign endometriotic cysts (Figure 3E). The
representative figures of Western blot analysis of HIN-1
protein in samples with a methylated or unmethylated
HIN-1 promoter are shown in Figure 3F. The protein
level of HIN-1 also had reversely correlated with the pro-
moter methylation status in OCCA tissues. HIN-1 pro-
tein levels in OCCA samples were further checked by
immunohistochemistry (Figure 3G). Reduced or absent
expression of HIN-1 was observed in 14 (42%) of 33
OCCA specimens. The percentage of HIN-1-expressing
in the HIN-1-promoter unmethylated OCCA were sig-
nificantly higher than that in those on the HIN-1-
promoter methylated OCCA (74% (14/19) vs. 32% (5/14),
p = 0.029 chi-square test).
Our results indicate that both of the mRNA and pro-
tein levels of HIN-1 were lower in specimens with a
methylated promoter as compared to those with an
unmethylated promoter.
HIN-1
Figure 1 (A) Overall survival differences in OCCA patients with methylated and unmethylated HIN-1. (p =0.002, by the log-rank test)
(B) Overall survival differences between OCCA patients with methylated and unmethylated CACNA1A. (p =0.02, by the log-rank test).
Figure 2 MS-MLPA and MS-PCR probes and amplicon locations of the HIN-1 gene promoter.









Figure 3 (A) Summary of bisulphite sequence results of HIN-1 in OCCA cell lines. The specific CpG sites detected by MS-PCR were almost
completely in accordance with bisulphite sequencing of HIN-1. (B) Promoter methylation of HIN-1 in OCCA cell lines detected by MS-PCR.
(C) Summary of bisulphite sequence results of HIN-1 in OCCA tissues. (D) Promoter methylation of HIN-1 in OCCA cell lines detected by MS-PCR.
(E) The mRNA expression of HIN-1 correlated well with the methylation status in OCCA cell lines and cancerous tissues, ovarian serous cancers,
and benign endometriotic cysts. (F) Representative figures between the methylation status and protein expression of HIN-1 by Western blot
analysis. Samples 55 and 68 were OCCA tissues with HIN-1 methylation. Samples 50, 86, 04, and 08 were OCCA tissues without methylation.
Samples B30 and B31 were benign endometriotic cysts. (G) Immunohistochemical staining of HIN-1. E1: Endometriotic cyst tissue (40x10),
E2: HIN-1 overexpression from OCCA (sample 68 with unmethylated HIN-1, 40x10), E3: loss of HIN-1 expression from OCCA (sample 50 with
methylated HIN-1, 40x10).
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could be restored by the demethylating agent
To verify the role of DNA methylation and the level of
expression of the HIN-1 gene, fully methylated KK cancer
cells were treated with the demethylating agent, 5-aza-2-
dC at 0, 24, 48, 72, 96 hours, and the density of unmethy-
lated band of HIN-1 gene was gradually reversed after 48
hoursdetected by MS-PCRe shown in Figure 4A. After
normalization, relative HIN-1 mRNA levels in KK cells
significantly increased after treatment with 5-aza-2-dC
when the duration extended (Figure 4B), which is corre-
lated with HIN-1 DNA methylation (Figure 4A).Overexpression of HIN-1 enhanced ES-2 cells sensitivity to
paclitaxel
We then evaluated cell growth and the viability of ES-2
cells stably transfected with HIN-1 full-length cDNA or
an empty vector (EV) as ES-2-HIN-1, and ES-2-
PCDNA3.1 cells. mRNA and protein levels of HIN-1
were significantly higher in ES-2-HIN-1 cells than in
ES-2-PCDNA3.1 cells (p < 0.0001) (Figure 4C and D).
In addition, ES-2-HIN-1 cells showed significantly
slower growth than ES-2-PCDNA3.1 cells (p < 0.0001)
(Figure 5A). Furthermore, ES-2-HIN-1 cells had signifi-


















































Figure 4 (A) The representative figure of mRNA expression of
HIN-1 in KK cells treated with 5-aza-2-dC at different time
intervals. (B) mRNA expression of HIN-1 in KK cells treated with
5-aza-2-dC. After normalization, the relative HIN-1 mRNA level
significantly increased in KK cells by 5-aza-2-dC. (C) mRNA levels of
ES-2 transfectants. mRNA levels of ES-2 cells transfected with HIN-1
were significantly higher than those of ES-2 transfected with EV
(p< 0.0001) (D) HIN-1 protein expression levels of ES-2 transfectants.
Protein levels of ES-2 cells transfected with HIN-1 were significantly
higher than those of ES-2 transfected with EV (p< 0.0001).























vector alone (7.5nM Taxol)
over HIN-1 (7.5nM Taxol)
vector alone (15nM Taxol)
over HIN-1 (15nM Taxol)
(A)
(B)
Figure 5 (A) Cell growth assays of various ES-2 transfectants
treated with paclitaxel. Paclitaxel inhibited cell growth of ES-2
transfectants in a dose-dependent manner. In addition, the
inhibitory effects of paclitaxel on cell growth were higher in the ES-2
HIN-1 transfectant than in EV-transfected ES-2 cells (circles,
p= 0.0001; triangles, p= 0.0005; squares, p= 0.0008). (B) Caspase
activities of various ES-2 transfectants. Caspase-3 activities of ES-2
HIN-1 transfectants were higher compared to those of
EV-transfected ES-2 cells (for 5 days * p< 0.05; for 7 days,
** p< 0.001).
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2-PCDNA3.1 cells, when treated with paclitaxel
(p < 0.01, onw-way ANOVA) (Figure 4A and B).
To study the possible role of HIN-1 in the sensitivity
of OCCA cells to paclitaxel, ES-2-HIN-1 cells were trea-
ted with various concentrations of paclitaxel. As shown
in Figure 6A, paclitaxel could induce higher percentages
of apoptosis in ES-2-HIN-1 tumor cells than those of
vector alone ES-2 tumor cells. Regardless being treated
with paclitaxel (Figure 6A) or cisplatin (Figure 6B), ES-
2-HIN-1 cells had higher numbers of Annexin-V-
positive cells than ES-2-PCDNA3.1 cells (p < 0.001). In
addition, caspase-3 activities detected in ES-2-HIN-1cells were also significantly higher than those detected in
ES-2-PCDNA3.1 cells, regardless of whether they were
treated with paclitaxel (p < 0.01, Figure 6C) or cisplatin
(p < 0.01, Figure 6D).
We further evaluated if the HIN-1 would influence
the phosphorylation of Akt. As shown in Figure 6E,
the paclitaxel could reduce the phosphorylation of
Akt at thr308, but not at Ser473 in ES-2-HIN-1
cells.
Our results indicate that restoration of HIN-1 can en-
hance the susceptibility of cytotoxic drugs and increase
the apoptosis-related enzyme activities in H1N-1-
transfected cancer cells by influencing the Akt
phosphorylation.
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Figure 6 (A) Representative figures of apoptotic assays of various ES-2 transfectants treated with paclitaxel. (B) Representative
figures of apoptotic assays of various ES-2 transfectants treated with cisplatin. ES2 cells without (a-d) or with (e-h) HIN-1 overexpression.
The induction of apoptosis is indicated as black arrows in VL (panel e) and white arrows in the overlay (panel h). Late apoptosis is
represented as yellow arrows in panel h. VL, visible light; PI, propidium iodide. Bar, 50 μm. (C) Caspase-3 activities of various ES-2
transfectants treated with paclitaxel. Increasing caspase-3 activities were shown by ES-2 HIN-1 transfectants compared to EV-transfected
ES-2 cells, when treated with paclitaxel. (* p< 0.05) (D) Caspase-3 activities of various ES-2 transfectants treated with cisplatin. Increasing
caspase-3 activities were shown by ES-2 HIN-1 transfectants compared to EV-transfected ES-2 cells, when treated with cisplatin
(* p< 0.05, ** p< 0.001). (E) Akt Phosphorylation in HIN-1-overexpressed ES-2 cells. Western blots for phospho-Akt (p-Akt) and total-Akt
(t-Akt) were prepared from ES-2 cells treated with 15 nM paclitaxel for 0 h, 1 h, 3 h, 6 h, or 24 h. A marked decrease of p-Akt (Thr308)
was observed. α-tubulin was as a loading control.
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The present study evaluated the application of a multi-
plex methylation technique to analyze promoter methy-
lation of TSGs in OCCAs. When we tested OCCA cell
lines and cancerous tissue specimens, and compared
them with ovarian serous carcinomas, different methyla-
tion profiles of TSG promoters in OCCA were noted.
We then tested promoter methylation frequencies of tar-
geted TSGs in benign endometriotic cysts, which are
regarded as precursor lesions in OCCA and compared
those with OCCA and non-OCCA tissues. The percen-
tages of promoter hypermethylation of RASSFIA,
CCND2, CDH13, CACNA1A, HIN-1, sFRP5, ID4, APC,
GSTP1, and TP73 were found from 77% to 6% of
OCCAs, respectively, whereas there was little promoter
methylation in benign ovarian endometriotic cysts.
The methylation frequencies of RASSFIA, CDH13,
CACNA1A, HIN-1, DKN2B, sFRP5, ID4, and ESR were
significantly higher in the clear-cell type of ovarian car-
cinoma than in the non-clear-cell type. In this study, we
included genes with crucial roles in DNA repair and cell
cycle control, transcriptional regulation, cell differenti-
ation and proliferation, cell adhesion, DNA damage and
apoptosis, and detoxification. Our data are in accordance
with previous reports showing altered methylation pat-
terns of a panel of genes in ovarian cancer, including
genes encoding RASSFIA, HIN-1, APC, BRCA1, CASP8,
CDH13, CDKN2A, CDKN2B, GSTP1, MLH1, PTEN,
RASSF1, TIMP3, sFRP4, sFRP5, CCND2 and TP73,
which had various promoter methylation extents above
the 30% threshold [9,22,23].
Promoter methylation of CACNA1A is associated with
OCCA. Our study identified eight candidate genes with
promoter methylation in OCCA including CACNA1A
and HIN-1, which were significantly higher than those
of the non-clear-cell type of ovarian carcinoma. This is
the first report of promoter methylation of CACNA1A
associated with the carcinogenesis of OCCA. In contrast,
promoter methylation of CACNA1A was not found in
benign endometriotic cysts, and was at a low frequency
in ovarian serous carcinoma in this study. Methylation
of CACNA1A is involved in the carcinogenesis of
OCCA without endometriosis. Promoter methylation of
HIN-1 and CACNA1A represents two novel epigenetic
events associated with outcomes of patients with OCCA.
The biological significance of the methylation of these
two aberrant genes with carcinogenesis of OCCA
deserves further investigation.
The MS-MLPA offered a good approach to test and
improve the histopathologic stratification and prognostic
prediction of cancers. Castro et al. reported that MS-
MLPA can be used to classify certain types of lung can-
cers and predict clinical outcomes of patients, and offers
an alternative strategy for clinically managing suchpatients [19]. Among the high-throughput techniques
available today for epigenetic alteration assessment, the
CpG array represents the main comprehensive platform
which has been applied to identify methylation candi-
dates in ovarian cancer [24,25]. However, the CpG array
is not feasible for DNA extracted from paraffin-
embedded tissues. Advantages of the MS-MLPA tech-
nique applied in this study include several aspects such
as allowing the screening of promoter methylation of
multiple genes in one experiment using a low amount of
DNA (around 150 ng), being feasible for using DNA
extracted from paraffin-embedded tissues (near half in
our OCCA samples), providing semiquantitative data,
and requiring only standard laboratory equipments.
Advantages of the MS-MLPA using a methylation-
sensitive digestion technique, compared to MS-PCR, can
omit the potentially troublesome bisulfite conversion of
unmethylated cytosines required by the MS-PCR.
Methylation indices for the majority of the probes were
consistent and reproducible. Variations in methylation
ratios obtained for each probe revealed inter-assay re-
producibility reliable enough for clinical practice.
To further validate the promoter methylation of HIN-
1, two specific regions of promoter methylation of the
HIN-1, MS-PCR-1 and MS-PCR-2 amplicons were
designed in this survey. These two amplicons overlapped
specific sites designed for MS-MLPA of HIN-1. We fur-
ther used MS-PCR and sodium bisulfite sequencing to
validate the specific sites of methylation in OCCA cell
lines and cancerous tissues obtained from MS-MLPA. A
good correlation of the methylation status between MS-
MLPA and MS-PCR was found. We also identified that
methylation of HIN-1 downregulated the expression of
HIN-1 in OCCA cell lines and cancerous tissues accord-
ing to RT-PCR, Western blot, and IHC analyses. In
addition, HIN-1 expression in the KK cell line (fully
methylated HIN-1 gene) was restored by the demethyla-
tion reagent, 5-aza-2-dC.
Identifying different methylation profiles in OCCA cell
lines provided initial insights into the potential impacts
of these candidate genes on OCCA patients. In our
series, results for OCCA tissues obtained by MS-MLPA
concurred with those of OCCA cell lines, which sup-
ported the cancer specificity of the methylated candi-
dates. Our results are also in line with previous reports
describing methylation of some candidates in ovarian
cancer, such as RASSF1A, CCDN2, CDH13, CACNA1A,
HIN-1, SFRP5, ID4, APC , RUX3, GSTP1, TP73, and
TIMP3. It is important to be aware that aberrant methy-
lation needs to meet the cutoff ratio of ≥ 30% set by the
mathematical algorithm designed to distinguish legitim-
ate methylation peaks. Near half of the OCCA samples
in our study were paraffin-embedded tissues, which were
microdissected, to prevent contamination by normal (U)
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unmethylated promoter next to methylated sequences
is usually disregarded as originating from normal tissue.
MS-MLPA is only based on one or two CpG sites com-
pared to an average of four to six CpG sites in MS-
PCR assays. Since only a small region of the promoter
is analyzed with the MS-MLPA method, the methyla-
tion of nearby CpG islands cannot be excluded and
should be validated by MS-PCR and sodium bisulfite
sequencing.
DNA hypermethylation of TSGs plays an important
role in ovarian carcinogenesis [9,20,21]. Our data sup-
port the concept that promoter hypermethylation is a
common mechanism involved in ovarian carcinogenesis,
and 11 target genes (RASSF1A, CCDN2, CDH13, CAC-
NA1A, HIN-1, sFRP5, ID4, APC, RUX3, GSTP1, and
TP73) novel to OCCA were identified. These results
highlight the importance of epigenetic regulation of dif-
ferent types of ovarian cancer. In particular, promoter
methylation of HIN-1 was found to be a independent
prognostic factor of OS in OCCA.
HIN-1 encodes a small, 10-kDa secreted protein,
secretoglobin 3A1, which belongs to the secretoglobin
family [24]. Mice with homozygous deletion of HIN-1
are predisposed to develop spontaneous malignancies
[26]. Recent reports showed that HIN-1 expression is
downregulated in the majority of lung, breast, prostate,
pancreatic, colorectal, testicular, and nasopharyngeal
cancers, and this downregulation is associated with
hypermethylation of the HIN-1 promoter [27-30]. Thus,
silencing of HIN-1 expression by promoter methylation
is an early and frequent event in multiple human cancer
types, functionally relevant to tumorigenesis [27]. To-
gether with the in vitro data on growth inhibition and
Akt activation in breast cancer, these results suggest that
HIN-1 is a candidate tumor suppressor gene [31]. We
demonstrated herein that the frequently of HIN-1 pro-
moter hypermethylation occurs in OCCA but less often
in non-OCCA-type epithelial ovarian cancer, suggesting
that this event may also play a role in the development
of a subgroup of these tumors. We further confirmed
that HIN-1 is downregulated by promoter methylation
and functions as a tumor suppressor gene through inhi-
biting cell growth and inducing apoptosis in OCCA cells.
Furthermore, overexpression of HIN-1 enhanced ES2
cell sensitivity to paclitaxel and cisplatin through signifi-
cantly inhibiting cell growth and increasing early and
late apoptosis, which supports the results of HIN-1 pro-
moter methylation with downregulation of HIN-1 ex-
pression causing poor survival outcomes in OCCA
patients. From the results of reducing phosphorylated
Akt at thr308, ectopic expression of the HIN-1 gene in
OCCA cells increased paclitaxel sensitivity which is pos-
sibly through the Akt pathway.OCCA is usually more resistant to systemic chemo-
therapy than other types and has a poorer prognosis
[3-5]. Almost all OCCA patients undergo subsequent
adjuvant chemotherapy, with a combination of taxane
and platinum compounds which are the most fre-
quently applied regimens. The lack of effective chemo-
therapy for recurrent OCCA after frontline treatment is
another important clinical problem. Therefore, to im-
prove the survival of patients with OCCA, the develop-
ment of novel treatment strategies in the setting of
both first-line and salvage treatments of recurrent
disease is urgently needed. If the sensitivity to taxane-
based chemotherapy can be enhanced, it would repre-
sent improved clinical management of this disease. In
the present study, whether methylation of HIN-1 or
CACNA1A gene could predict survival and also act as
a prognostic indicator when treating OCCA patients.
Our study provides novel and useful information for
planning treatment strategies of OCCA. In this study,
overexpression of HIN-1 enhanced ES2 cell sensitivity
to paclitaxel and cisplatin through inhibiting cell
growth and enhancing apoptosis. Restoration of the
function of HIN-1 would be an important step to de-
velop new treatment strategies with demethylating
agents or histone deacetylating inhibitors for OCCA
patients with HIN-1 methylation. The underlying
mechanisms and pathways regulating the HIN-1 gene
in OCCA urgently need to be explored.
Recently, CACNA1A was identified as a novel tumor
suppressor candidate, the promoter of which is methy-
lated in lung and prostate tumors [19-32]. CACNA1A
was implicated in diseases of the brain, regulated by
HIF-2α [33]. Anglesio et al. pointed out the importance
of IL6-STAT3-HIF signaling and the promising re-
sponse to the angiogenesis inhibitor, sunitinib, in
OCCA patients [33], and suggested that more-extensive
clinical trials with sunitinib in OCCA were warranted.
Intriguingly, HIN-1 was also identified as a direct HIF-
2α-targeted gene, and it was demonstrated that HIF-2α
regulates HIN-1 expression and tumor formation in
human rasG12D-driven NSCLC cells [34]. Akt pathway
activity repressed by HIN-1 was enhanced in HIF-2α-
deficient human NSCLC cells and xenografts [35]. The
role of HIF-2α regulation in OCCA needs to be
explored.
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